These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20954379)

  • 21. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
    Petrioli R; Pascucci A; Francini E; Marsili S; Sciandivasci A; De Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
    BJU Int; 2007 Oct; 100(4):775-9. PubMed ID: 17535276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM; Ryan CW; Venner PM; Petrylak DP; Chatta GS; Ruether JD; Redfern CH; Fehrenbacher L; Saleh MN; Waterhouse DM; Carducci MA; Vicario D; Dreicer R; Higano CS; Ahmann FR; Chi KN; Henner WD; Arroyo A; Clow FW;
    J Clin Oncol; 2007 Feb; 25(6):669-74. PubMed ID: 17308271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New progress in treatment of hormone-refractory prostate cancer.
    Ahmad K
    Lancet Oncol; 2004 Dec; 5(12):706. PubMed ID: 15599999
    [No Abstract]   [Full Text] [Related]  

  • 25. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
    Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
    Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.
    Nelius T; Klatte T; de Riese W; Filleur S
    Int Urol Nephrol; 2008; 40(1):97-104. PubMed ID: 17602304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
    Van Poppel H
    Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
    Olbert PJ; Weil C; Hegele A; Hofmann R; Schrader AJ
    Aktuelle Urol; 2009 May; 40(3):164-8. PubMed ID: 19370533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
    Perry CJ; Sundar S
    Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan.
    Fukuta F; Kitamura H; Yanase M; Taguchi K; Takahashi A; Kunishima Y; Miyake M; Adachi H; Itoh N; Hirose T; Takagi S; Miyao N; Matsukawa M; Shigyo M; Masumori N
    Jpn J Clin Oncol; 2015 Jul; 45(7):682-7. PubMed ID: 25862824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report].
    Miyake M; Nakaigawa N; Kita K; Yanagisawa M; Terao H; Sano F; Murakami T; Makiyama K; Ogawa T; Uemura H; Yao M; Kubota Y
    Hinyokika Kiyo; 2010 Jan; 56(1):45-8. PubMed ID: 20104010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer].
    Shimasaki T; Miyazawa K; Moriyama M; Tanaka T; Sato I; Nakaya N; Nakajima H; Kubo A; Suzuki K; Motoo Y
    Hinyokika Kiyo; 2011 Mar; 57(3):163-6. PubMed ID: 21586891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Two cases of pellagra associated with chemotherapy of docetaxel, estramustine, dexamethasone].
    Yokomizo Y; Fujikawa A; Tajiri T; Ota J; Yumura Y; Moriyama M; Mouri S
    Hinyokika Kiyo; 2010 Oct; 56(10):585-8. PubMed ID: 21063165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone.
    Caffo O; Sava T; Comploj E; Giampaolo MA; Segati R; Valduga F; Cetto G; Galligioni E
    Urol Oncol; 2010; 28(2):152-6. PubMed ID: 18848786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
    Goodin S; Rao KV; Kane M; Dave N; Capanna T; Doyle-Lindrud S; Engle E; Jin L; Todd M; DiPaola RS
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):199-204. PubMed ID: 15838657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
    Wolff JM
    Onkologie; 2003 Dec; 26 Suppl 7():37-40. PubMed ID: 14716141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.